Rigerna Biosciences Appoints Dr. Du Zhiqiang as New Chief Operating Officer to Accelerate Global Oligonucleotide Therapeutics Pipeline

Apr 23, 2025 08:21 CST Updated 08:21

Rigerna

Innovative Small Nucleic Acid Drug Developer

Recently, Suzhou Rigerna Therapeutics (referred to as "Rigerna") officially appointed Dr. Du Zhiqiang (Du Zhiqiang), a senior expert in drug research and development, as the company's COO. He will be fully responsible for the pipeline development of small nucleic acid innovative drugs, improving and accelerating the industrialization process of the pipeline, promoting and expanding the company’s international cooperation and overall influence.

Du Bo has nearly 20 years of experience in drug research and development and enterprise management, and has worked atNovartis、Johnson & Johnson、AmgenSuch as holding core R&D and leadership roles in well-known MNC pharmaceutical companies; in recent years, at large listed companies in ChinaShanghai Renhui Biotechnology Co., Ltd.AndTonghua Dongbao Pharmaceutical Co., Ltd.Serving as Vice President, in charge of R&D.Du Bo has extensive experience in target initiation, drug development, registration submission, clinical medicine, and company operations management, with particularly profound insights and notable achievements in the field of chronic diseases.

Du BoJoining Rigerna as COO will primarily be responsible for: the R&D project initiation of the company’s innovative pipeline and its forward-looking, strategic layout; leading the preclinical research, regulatory submissions, clinical development, and the linking and maintenance of related resources for the R&D center's ongoing pipeline; promoting and expanding the company’s international operations, cooperation, and development, among other crucial tasks.

Rigerna

Chairman Dr. Huang Yuanyu:

siRNA innovative drugs are reshaping the biopharmaceutical landscape with their tremendous potential and promising future. Rigerna, rooted in China and oriented globally (In China, For Global), is committed to becoming a next-generation small nucleic acid drug development company driven by innovative technology. We sincerely thank Dr. Du for his full recognition of Rigerna and its team. Dr. Du brings extensive experience in clinical medicine, translational medicine, new drug R&D, and corporate operations management, as well as exceptional international vision. We look forward to working together with Dr. Du and colleagues to further enhance the company’s professional capabilities, pipeline layout, and global development process, fulfilling the company’s vision and bringing benefits to human health as soon as possible.

Rigerna

Chief Operating Officer Dr. Du Zhiqiang:

I am very honored to join the Rigerna team, which is a very important milestone in my career. The core team of the company has profound accumulation and extremely strong technical foundation and strength in the field of nucleic acid pharmaceuticals, making it a highly potential and competitive innovative nucleic acid drug development company. I am glad to work with everyone wholeheartedly and spare no effort to help the company achieve more successes in product pipelines, industrial operation, and international development.

Rigerna

About Rigerna

Suzhou Rigerna Therapeutics and Beijing Rigerna Pharma Technology Co., Ltd. (Rigerna) were established in 2022. The company focuses on the research and development and industrialization of innovative small nucleic acid drugs, with a foundation in China and a vision for global impact (In China, For Global), committed to becoming a leader and innovator in the field of nucleic acid pharmaceuticals. The company has brought together a core team with over 10 years of industry experience, possessing extensive expertise in nucleic acid biology, nucleic acid chemistry, liver and non-liver delivery, project management, pharmaceutical research, regulatory submissions, and clinical development. Rigerna has established a globally proprietary intellectual property platform, RIHOST, addressing key technological bottlenecks, intellectual property barriers, and future directions in this field.^®、RICMO^®、LICOD^®...and other core technology platforms, Rigerna has established multiple in vivo delivery technologies for non-liver tissues based on various exclusive strategies, making it a global leader in non-liver delivery technology and pipeline development. The company has a deep understanding and differentiated considerations in target and indication selection. Its liver-targeting product is about to enter Phase II clinical trials, with the progress leading globally. It will also rapidly advance the development of a series of small nucleic acid drugs for non-liver tissues, bringing benefits to patients.

E.N.D

Previous article recommendations:(Click the article title below to open the original text)

Comprehensive Analysis of Stem Cell Therapy Bioprocessing and Regulatory Landscape

China’s First Stem Cell Clinical Research Project for Major Pediatric Diseases Shows Significant Results, Enabling Children with Cerebral Palsy to Walk Independently from Being Unable to Stand

A Suzhou Rigerna Therapeutics, a company focused on the cell therapy field, has commenced operations and production in China.

World's First Breakthrough Clinical Research Achievement of Intrathecal Injection of Treg Cells for ALS Released

China's First Allogeneic Universal Regenerative Islet Transplantation Therapy for Type 1 Diabetes Approved for IND

A Cell Therapy Company in China Secures New Round of Financing

Stock Price Surges Nearly 40%! AAV Gene Therapy AMT-130 Receives Breakthrough Therapy Designation

China's First Hospital-Grade iPSC Technology Platform Launched

Rao Yi's Gene Therapy Company, Huayi Lejian, Announces New Chief Medical Officer

Up 135% Year-on-Year! Rigerna's CAR-T Cell Therapy Product Rakes in $369 Million in Q1

Output Soars 345%! New Low-Cost Cell Culture Technology to Reshape MSC High-Efficiency Production Paradigm

A Cell Therapy Company in China Completes Tens of Millions in Angel Financing

Latest Clinical Progress of the World's First Glaucoma Gene Therapy – Beijing Tongren Hospital Completes Dosing in 2 Patients

Nature | New Breakthrough in Gene Editing! Achieving Highly Efficient Integration of Large Gene Fragments, Could Lead to a New Generation of Gene Therapy Drugs

China's First AAV Gene Drug Approved for Marketing!

The Number of Gene Therapy Drugs Listed in China Increases to 9

CDE Releases "Common Issues and Answers on the Chemistry of Recombinant Adeno-Associated Virus Vector In Vivo Gene Therapy Products for Marketing Application (Draft for Comments)"

Construction of a GMP Facility for Cell Drug Production Officially Begins in China

Maximum Single Award of 30 Million Yuan, Focusing on Cell Drugs, Nucleic Acid Drugs, Protein Drugs and Other Directions, Shenzhen Fully Supports Pharmaceutical R&D and Introduction

Promoting High-Quality Development of Innovative Pharmaceuticals like Cell and Gene Therapy, Beijing Municipal Medical Security Bureau and Other Nine Departments Issue New Policies

A Cell Therapy Company in China Completes Pre-A Round Financing

SoundNote: The content is sourced from the company's official channels.WenPurposeInKnowKnowledge SharingAll content is for reference only and does not constitute any advice.